What is proper cancer care in the era of managed care?

Managed care and proper cancer care need not be mutually exclusive entities. Managed-care organizations (MCOs) that are committed to patients and society should have the following characteristics: accountability for results, cost containment, measurement of outcomes, health promotion and disease prevention programs, resource consumption management, emphasis on primary care, and continuous quality improvement. Whether these commitments are upheld depends on when and with whom the MCO contracts to provide care and which medical and quality assurance protocols it follows. If proper cancer care is to become a reality in the managed-care era, the oncology community must take a proactive stance. Oncologists must provide the market with an appropriate, efficient disease management plan for cancer. In concert with MCOs, the oncology community must define and, through partnerships, promote the seamless integration of proper cancer care. Patients and advocates should insist that MCOs' quest for efficiency allows for flexibility to address individual patients' circumstances.

[1]  M. J. Hoeksema,et al.  Cancer mortality rates fall: a turning point for the nation. , 1996, Journal of the National Cancer Institute.

[2]  P. Kantoff,et al.  NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network. , 1996, Oncology.

[3]  J. Moul,et al.  Age-specific reference ranges for serum prostate-specific antigen in black men. , 1996, The New England journal of medicine.

[4]  J. Moul,et al.  Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. , 1996, The Journal of urology.

[5]  J. Oesterling,et al.  Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. , 1995, The Journal of urology.

[6]  S. Woolf Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. , 1995, The New England journal of medicine.

[7]  W. Catalona,et al.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.

[8]  R. Abrams,et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. , 1995, Urology.

[9]  R. Morton,et al.  Racial differences in adenocarcinoma of the prostate in North American men. , 1994, Urology.

[10]  C. Bangma,et al.  Age-specific reference ranges for prostate-specific antigen. , 1994, JAMA.

[11]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[12]  Boris Rubinsky,et al.  Transrectal ultrasound‐guided percutaneous radical cryosurgical ablation of the prostate , 1993, Cancer.

[13]  G. P. Monaco The Partnership of Empowerment , 1992 .

[14]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[15]  G. D'angio Cure Is Not Enough: Late Consequences Associated with Radiation Treatment , 1988, Journal of the Association of Pediatric Oncology Nurses.

[16]  A. Meadows The Concept of Care for Life , 1988, Journal of the Association of Pediatric Oncology Nurses.

[17]  S. Sharfstein From Advocacy to Allocation: The Evolving American Health Care System , 1987 .

[18]  F. Mullan The Cancer Consort , 1987 .

[19]  Wittes Re Paying for patient care in treatment research--who is responsible? , 1987 .

[20]  P. Wingo,et al.  Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.

[21]  Curtis Mettlin,et al.  Defining and updating the american cancer society guidelines for the cancer‐related checkup: Prostate and endometrial cancers , 1993, CA: a cancer journal for clinicians.

[22]  G. P. Monaco Moving ahead in cancer research: who pays for patient supportive care for participation in experimental/investigational trials? , 1991, Cancer investigation.

[23]  R. Wittes Paying for patient care in treatment research--who is responsible? , 1987, Cancer treatment reports.